Interna Therapeutics

Company Overview

Snapshot

Founded in October 1996 by Ilan Ziv, Interna Therapeutics operates with 11–50 employees. The company has raised a total of $57.55 million across 5 funding rounds from 10 investors.

Business overview

Interna Therapeutics is an innovative biotechnology company focused on developing a transformational delivery technology for macromolecules. Its core technology, Molecular Nano-Motors (MNMs), leverages membrane electrical forces to facilitate the entry of charged molecules into cells. This technology enables new treatment options for a wide range of diseases using difficult-to-deliver molecules, such as oligonucleotide-based drugs (siRNA, ASO). The company serves the pharmaceutical and life sciences industries, operating within the Health Tech & Life Sciences sector, specifically in Drug Delivery.

Strategic signal

In April 2026, Interna Therapeutics announced a research collaboration with Daiichi Sankyo to advance its MNM-based targeted delivery technologies. This partnership signals strong external validation of Interna's proprietary Molecular Nano Motor platform and its potential to enhance drug delivery, indicating a strategic move towards broader industry adoption and development of its core technology.

Company Intelligence Q&A

What is Interna Therapeutics' core technology?

Interna Therapeutics has developed Molecular Nano-Motors (MNMs), a technology that utilizes membrane electrical forces to facilitate the entry of charged molecules into cells, enabling the delivery of macromolecules for therapeutic purposes.

When did Interna Therapeutics merge with SirVir?

In November 2024, Interna Therapeutics announced a merger with SirVir, alongside a funding round led by Bill &.

Which organizations has Interna Therapeutics collaborated with on research?

Interna Therapeutics entered into a research collaboration with Bioasis Technologies Inc. in March 2021 and with Pfizer in September 2015. In April 2026, the company announced a research collaboration with Daiichi Sankyo.

What was a significant licensing agreement for Interna Therapeutics?

In June 2020, Processa Pharmaceuticals entered into an agreement with Interna Therapeutics (then Aposense, Ltd) to license in the next-generation Irinotecan drug.

When did Interna Therapeutics (then Aposense) report positive drug results for colon cancer?

In January 2014, Interna Therapeutics, operating as Aposense, reported positive results for its colon cancer drug.